Caxton Associates Accumulates 5.1% Stake in Tercica (TRCA)
More News related to TRCA
- Tercica (TRCA) Reports Q2 loss of $0.22
- Tercica Reports Second Quarter 2008 Financial Results
- Ipsen Continues the Acquisition Process of Tercica so as to Establish Its Global Presence in Endocrinology
- Caxton Associates Accumulates 5.1% Stake in Tercica (TRCA)
- Tercica (TRCA) Reports Results from Increlex(R) IGFD Patient Registry
In a 13G filing after the close on Tercica Inc. (Nasdaq: TRCA), Caxton Associates disclosed a 5.1% stake (2,629,164 shares) in the company. The firm did not show a stake in TRCA at the quarter ended 03/31/08.
Tercica, Inc., a biopharmaceutical company, engages in the development and marketing of endocrine products.
Caxton Associates, L.L.C., is a $14 bilion New York-based hedge fund, founded in 1983 by Bruce Kovner. Caxton Associates' primary business is to manage client and proprietary capital through global macro hedge fund strategies as well as other alternative investment disciplines.
Link to More Caxton Associates News. StreetInsider.com Premium Members Can Set Up E-Mail Alerts for Caxton Associates. FREE TRAIL.
Related Categories
13GsStocks Mentioned
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
